壽仙谷(603896.SH):子公司擬簽訂壽仙谷數智中心工程施工合同
格隆匯9月29日丨壽仙谷(603896.SH)公佈,2024年9月,公司對杭政儲出[2024]18號地塊商業商務用房壽仙谷數智中心建設項目施工總承包邀請了杭州天河建設集團有限公司、浙江耀華建設集團有限公司、杭州中敏建設工程有限公司等進行了商務談判,經多方評比,確定杭州中敏建設工程有限公司(簡稱“杭州中敏”)為成交單位。公司於2024年9月29日召開第四屆董事會第二十四次會議審議通過了《壽仙谷關於全資子公司擬簽訂壽仙谷數智中心工程施工合同的議案》。本次合同總價暫定為人民幣3.5億元,本次合同總價約佔公司2023年度經審計淨資產的16.12%,約佔公司2023年度經審計營業收入的44.62%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.